Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran.


Treatment of acute venous thromboembolism (VTE) and prophylaxis of recurrent events has been investigated in the THRIVE (THRombin Inhibitor in Venous Thrombe Embolism) Treatment and the THRIVE III trial using the oral direct thrombin inhibitor ximelagatran. Alanine aminotransferase (ALAT) increased in 9.6% and 6.4% of patients in the THRIVE Treatment and… (More)

3 Figures and Tables


  • Presentations referencing similar topics